Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Mucosal Immunol ; 4(3): 304-13, 2011 May.
Article in English | MEDLINE | ID: mdl-21068720

ABSTRACT

Peroxisome proliferator-activated receptor-γ (PPAR-γ) is widely expressed in macrophages and has been identified as a putative target for the development of novel therapies against inflammatory bowel disease (IBD). Computational simulations identified macrophages as key targets for therapeutic interventions against IBD. This study aimed to characterize the mechanisms underlying the beneficial effects of macrophage PPAR-γ in IBD. Macrophage-specific PPAR-γ deletion significantly exacerbated clinical activity and colonic pathology, impaired the splenic and mesenteric lymph node regulatory T-cell compartment, increased percentages of lamina propria (LP) CD8+ T cells, increased surface expression of CD40, Ly6C, and Toll-like receptor 4 (TLR-4) in LP macrophages, and upregulated expression of colonic IFN-γ, CXCL9, CXCL10, IL-22, IL1RL1, CCR1, suppressor of cytokine signaling 3, and MHC class II in mice with IBD. Moreover, macrophage PPAR-γ was required for accelerating pioglitazone-mediated recovery from dextran sodium sulfate (DSS) colitis, providing a cellular target for the anti-inflammatory effects of PPAR-γ agonists in IBD.


Subject(s)
Colitis/immunology , Inflammatory Bowel Diseases/immunology , Macrophages/metabolism , PPAR gamma/metabolism , Animals , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Cells, Cultured , Colitis/chemically induced , Colitis/drug therapy , Colon/pathology , Computational Biology , Dextran Sulfate/administration & dosage , Disease Models, Animal , Gene Expression Regulation/immunology , Humans , Immunomodulation , Inflammatory Bowel Diseases/drug therapy , Macrophages/drug effects , Macrophages/immunology , Macrophages/pathology , Mice , Mice, Inbred C57BL , Mice, Mutant Strains , Microarray Analysis , Mucous Membrane/pathology , PPAR gamma/antagonists & inhibitors , PPAR gamma/genetics , PPAR gamma/immunology , Pioglitazone , T-Lymphocyte Subsets/drug effects , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , T-Lymphocyte Subsets/pathology , T-Lymphocytes, Regulatory/drug effects , T-Lymphocytes, Regulatory/immunology , T-Lymphocytes, Regulatory/metabolism , T-Lymphocytes, Regulatory/pathology , Thiazolidinediones/pharmacology , Thiazolidinediones/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...